Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Celladon Corporation Stories

2013-12-11 08:31:07

--Ongoing CUPID 2 Study Potential to Serve as Primary Basis of Efficacy and Safety Required for MMA Submission in European Union-- SAN DIEGO, Dec. 11, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that the Company has received requested scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the...

2013-11-18 16:29:35

--Continued reduction in cardiovascular events and no safety concerns observed through three years of follow up in the MYDICAR high dose group-- SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that on behalf of the CUPID 1 Trial investigators, Dr. Barry H. Greenberg will present the full three year long-term follow up...

2013-10-18 08:24:44

SAN DIEGO, Oct. 18, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that it has appointed Michael Narachi as Chairman of the Board of Directors. Michael currently serves as President and Chief Executive Officer of Orexigen Therapeutics, Inc. Michael has 29 years of biotechnology and pharmaceutical experience across a broad range...

2013-10-11 08:23:58

SAN DIEGO, Oct. 11, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock. All shares of the common stock to be sold in the offering will be offered by...

2013-09-26 12:29:24

--No safety concerns and reduction in cardiovascular events observed through three years of follow up in the MYDICAR high dose group-- SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced the full three year long-term follow up results from Phase 2a of the CUPID 1 trial in the online publication of Circulation...

2013-09-10 08:30:16

SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced today it has appointed Gregg Alton and Graham Cooper to its Board of Directors. "We are pleased to appoint Gregg and Graham to our Board of Directors," commented Krisztina Zsebo Ph.D., President and CEO of Celladon. "They each bring extensive experience in the...

2013-07-30 08:33:13

- MYDICAR When Inhaled May Restore Function of SERCA2a Enzyme in the Lungs to Reverse Deadly PAH Condition - SAN DIEGO, July 30, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company committed to applying its first-mover, leadership position in the field of SERCA enzymes to transform the lives of patients with important, life-threatening diseases, announced today that an international team of researchers led by investigators at the Cardiovascular Research Center...

2013-05-29 16:25:55

SAN DIEGO, May 29, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases announced today it had been selected as a winner of Red Herring's Top 100 North America award, a prestigious list honoring the year's most promising private technology ventures from the North American business region. "We are proud to have been selected as a winner of this award and we are thankful to our...

2013-05-08 08:31:23

-Analysis of Recurrent Heart Failure Hospitalizations in Presence of Informative Censoring - Application of Joint Frailty Model- SAN DIEGO, May 8, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it will present analysis methods for the MYDICAR development program at an upcoming Conference. The conference "Statisticians in the Pharmaceutical...

2013-05-07 12:31:43

SAN DIEGO, May 7, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases announced today it had been selected as a finalist for Red Herring's Top 100 North America award, a prestigious list honoring the year's most promising private technology ventures from the North American business region. Red Herring has been selecting the most exciting and promising start-ups and "scale ups"...